As COVID-19 Cases Surge, Here's What to Know About JN.1, the Latest SARS-CoV-2 Variant of Interest | Infectious Diseases | JAMA

This Medical News story discusses JN.1, recently classified as a SARS-CoV-2 “variant of interest” by the World Health Organization.

Related Keywords

Tokyo ,Japan ,Greece ,Greek ,Kei Sato ,David Montefiori ,Michael Osterholm ,Eric Topol ,William Schaffner ,Nicole Doria Rose ,University Of Tokyo ,University Of Minnesota ,Vanderbilt University School Of Medicine ,Public Health Emergency ,World Health Organization ,Us Centers For Disease ,Shionogi Co Ltd ,Scripps Research Institute ,Technical Advisory Group ,Takeda Pharmaceutical Co Ltd ,Gilead Sciences Inc ,Moderna Japan Co Ltd ,National Institute Of Allergy ,Infectious Disease Research ,Infectious Disease Vaccine Research Center ,Disease Control ,Humoral Immunology Core ,National Institute ,Vanderbilt University School ,Mass General Brigham ,Duke University Medical Center ,Advisory Group ,Health Emergency ,Interest Disclosures ,Gilead Sciences ,